Literature DB >> 16517093

Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy.

Jeremy D Ruben1, Michael Dally, Michael Bailey, Robin Smith, Catriona A McLean, Pasqual Fedele.   

Abstract

PURPOSE: To investigate radiation necrosis in patients treated for glioma in terms of incidence, outcomes, predictive and prognostic factors. METHODS AND MATERIALS: Records were reviewed for 426 patients followed up until death or for at least 3 years. Logistic regression analysis was performed to identify predictive and prognostic factors. Multivariate survival analysis was conducted using Cox proportional hazards regression. Separate analyses were performed for the subset of 352 patients who received a biologically effective dose (BED) > or =85.5 Gy2 (> or =45 Gy/25 fractions) who were at highest risk for radionecrosis.
RESULTS: Twenty-one patients developed radionecrosis (4.9%). Actuarial incidence plateaued at 13.3% after 3 years. In the high-risk subset, radiation parameters confirmed as risk factors included total dose (p < 0.001), BED (p < 0.005), neuret (p < 0.001), fraction size (p = 0.028), and the product of total dose and fraction size (p = 0.001). No patient receiving a BED <96 Gy2 developed radionecrosis. Subsequent chemotherapy significantly increased the risk of cerebral necrosis (p = 0.001) even when adjusted for BED (odds ratio [OR], 5.8; 95% confidence interval [CI], 1.6-20.3) or length of follow-up (OR, 5.4; 95% CI, 1.5-19.3). Concurrent use of valproate appeared to delay the onset of necrosis (p = 0.013). The development of radionecrosis did not affect survival (p = 0.09).
CONCLUSIONS: Cerebral necrosis is unlikely at doses below 50 Gy in 25 fractions. The risk increases significantly with increasing radiation dose, fraction size, and the subsequent administration of chemotherapy.

Entities:  

Mesh:

Year:  2006        PMID: 16517093     DOI: 10.1016/j.ijrobp.2005.12.002

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  130 in total

Review 1.  Headache in patients with cancer.

Authors:  Samuel A Goldlust; Jerome J Graber; Dana F Bossert; Edward K Avila
Journal:  Curr Pain Headache Rep       Date:  2010-12

2.  Development of a novel animal model to differentiate radiation necrosis from tumor recurrence.

Authors:  Sanath Kumar; Ali S Arbab; Rajan Jain; Jinkoo Kim; Ana C deCarvalho; Adarsh Shankar; Tom Mikkelsen; Stephen L Brown
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

3.  Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

Authors:  Mostafa Farzin; Michael Molls; Sabrina Astner; Ina-Christine Rondak; Markus Oechsner
Journal:  Strahlenther Onkol       Date:  2015-09-04       Impact factor: 3.621

Review 4.  Treatment of pediatric cerebral radiation necrosis: a systematic review.

Authors:  N Drezner; K K Hardy; E Wells; G Vezina; C Y Ho; R J Packer; E I Hwang
Journal:  J Neurooncol       Date:  2016-07-20       Impact factor: 4.130

5.  Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.

Authors:  Christina I Tsien; Doris Brown; Daniel Normolle; Matthew Schipper; Morand Piert; Larry Junck; Jason Heth; Diana Gomez-Hassan; Randall K Ten Haken; Thomas Chenevert; Yue Cao; Theodore Lawrence
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 6.  Radiation dose-volume effects in the brain.

Authors:  Yaacov Richard Lawrence; X Allen Li; Issam el Naqa; Carol A Hahn; Lawrence B Marks; Thomas E Merchant; Adam P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 7.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Authors:  Alba A Brandes; Alicia Tosoni; Federica Spagnolli; Giampiero Frezza; Marco Leonardi; Fabio Calbucci; Enrico Franceschi
Journal:  Neuro Oncol       Date:  2008-04-09       Impact factor: 12.300

8.  Is biopsy needed to guide management for all patients with presumed intracranial ectopic germinomas.

Authors:  Chenglin Tian; Chuanqiang Pu; WeiPing Wu; Xusheng Huang; Senyang Lang; Shengyuan Yu; Jiatang Zhang; Dehui Huang; Shuxiang Cui
Journal:  J Neurooncol       Date:  2008-10-26       Impact factor: 4.130

9.  Oligodendroglioma confers higher risk of radiation necrosis.

Authors:  Haroon Ahmad; David Martin; Sohil H Patel; Joseph Donahue; Beatriz Lopes; Benjamin Purow; David Schiff; Camilo E Fadul
Journal:  J Neurooncol       Date:  2019-09-23       Impact factor: 4.130

Review 10.  Identifying novel therapeutic agents using xenograft models of pediatric cancer.

Authors:  Raushan T Kurmasheva; Peter J Houghton
Journal:  Cancer Chemother Pharmacol       Date:  2016-05-18       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.